Sulpiride

Introduced 1968

Reviewed by the HeyPsych Medical Review Board

Board-certified psychiatrists and mental health professionals

Indications

Primary Indications

Schizophrenia and other psychotic disordersDepressive disorders (low-dose)Functional dyspepsiaVertigo

Mechanism

Selectively antagonizes dopamine D2 and D3 receptors, reducing mesolimbic dopamine overactivity to treat psychotic symptoms and modulating dopamine pathways involved in mood and gastrointestinal motility.

Dosing

Adult Dosing

oral: Schizophrenia: 400–800 mg/day in divided doses, up to 1600 mg/day. Depression/functional dyspepsia: 50–150 mg/day in divided doses.

Dosage Forms

Tablets: 50 mg, 100 mg, 200 mg
Capsules: 50 mg, 100 mg
Injection (IM): 100 mg/2 mL

Onset Duration

Improvement in psychiatric symptoms may be seen within 1–2 weeks; gastrointestinal symptom relief may occur within days.

Adverse Effects

Common Side Effects

• somnolence

• insomnia

• extrapyramidal symptoms

• hyperprolactinemia

• weight gain

⚠️ Serious Side Effects

neuroleptic malignant syndrome
tardive dyskinesia
QT prolongation

Warnings

Critical Safety Information

→May cause sustained hyperprolactinemia; monitor with long-term use
→Risk of QT prolongation—use caution with other QT-prolonging agents
→Increased mortality risk in elderly patients with dementia-related psychosis
→Avoid abrupt withdrawal to prevent relapse

Interactions

With: Levodopa

Risk: Reduced efficacy of antiparkinsonian therapy

Action: Avoid combination

With: Alcohol and CNS depressants

Risk: Increased sedation

Action: Avoid or monitor closely

With: QT-prolonging drugs

Risk: Increased risk of arrhythmia

Action: Avoid combination

Monitoring

Mental status and symptom control
Extrapyramidal symptoms
Weight, BMI, and metabolic profile
Prolactin levels

Special Populations

👶Pregnancy

Use only if benefits outweigh potential risks; possible neonatal withdrawal or extrapyramidal symptoms if used late in pregnancy.

🤱Breastfeeding

Excreted in breast milk; consider discontinuing breastfeeding or monitor infant closely.

👴Older Adults (65+)

Increased susceptibility to sedation, hypotension, and cardiac effects; start at lower doses.

Tapering

Gradually decrease dose over 1–2 weeks to minimize withdrawal symptoms and risk of relapse.

Clinical Notes

Low-dose sulpiride has antidepressant and gastrointestinal prokinetic activity
Commonly used outside the U.S. in psychiatric and gastroenterology practice
More likely than many antipsychotics to elevate prolactin levels

This medication information is for educational purposes only and is not a substitute for professional medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Never take medication without a prescription from a licensed healthcare provider.

Interested in this treatment?

This information is for educational purposes. Always consult with a qualified healthcare provider before starting any new treatment.

Locate Psychiatrists

Sulpiride

Introduced 1968

Reviewed by the HeyPsych Medical Review Board

Board-certified psychiatrists and mental health professionals

Indications

Primary Indications

Schizophrenia and other psychotic disordersDepressive disorders (low-dose)Functional dyspepsiaVertigo

Mechanism

Dosing

Adult Dosing

oral: Schizophrenia: 400–800 mg/day in divided doses, up to 1600 mg/day. Depression/functional dyspepsia: 50–150 mg/day in divided doses.

Dosage Forms

Tablets: 50 mg, 100 mg, 200 mg
Capsules: 50 mg, 100 mg
Injection (IM): 100 mg/2 mL

Onset Duration

Improvement in psychiatric symptoms may be seen within 1–2 weeks; gastrointestinal symptom relief may occur within days.

Adverse Effects

Common Side Effects

• somnolence

• insomnia

• extrapyramidal symptoms

• hyperprolactinemia

• weight gain

⚠️ Serious Side Effects

neuroleptic malignant syndrome
tardive dyskinesia
QT prolongation

Warnings

Critical Safety Information

→May cause sustained hyperprolactinemia; monitor with long-term use
→Risk of QT prolongation—use caution with other QT-prolonging agents
→Increased mortality risk in elderly patients with dementia-related psychosis
→Avoid abrupt withdrawal to prevent relapse

Interactions

With: Levodopa

Risk: Reduced efficacy of antiparkinsonian therapy

Action: Avoid combination

With: Alcohol and CNS depressants

Risk: Increased sedation

Action: Avoid or monitor closely

With: QT-prolonging drugs

Risk: Increased risk of arrhythmia

Action: Avoid combination

Monitoring

Mental status and symptom control
Extrapyramidal symptoms
Weight, BMI, and metabolic profile
Prolactin levels

Special Populations

👶Pregnancy

Use only if benefits outweigh potential risks; possible neonatal withdrawal or extrapyramidal symptoms if used late in pregnancy.

🤱Breastfeeding

Excreted in breast milk; consider discontinuing breastfeeding or monitor infant closely.

👴Older Adults (65+)

Increased susceptibility to sedation, hypotension, and cardiac effects; start at lower doses.

Tapering

Gradually decrease dose over 1–2 weeks to minimize withdrawal symptoms and risk of relapse.

Clinical Notes

Low-dose sulpiride has antidepressant and gastrointestinal prokinetic activity
Commonly used outside the U.S. in psychiatric and gastroenterology practice
More likely than many antipsychotics to elevate prolactin levels

Interested in this treatment?

This information is for educational purposes. Always consult with a qualified healthcare provider before starting any new treatment.

Locate Psychiatrists